Table 1.
Characteristics of nine trials eligible for meta-analysis
| Author | Martin et al11 | Sparano et al7 | Pallis et al12 | Crown et al15 | Miller et al26 | Thomas et al28 | O’Shaughnessy et al27 | Bonneterre et al25 | Albain et al29 |
|---|---|---|---|---|---|---|---|---|---|
| Year | 2007 | 2010 | 2012 | 2013 | 2005 | 2007 | 2002 | 2002 | 2008 |
| Country | Spain | USA | Greece | Ireland | USA | USA | USA | France | USA |
| Patients (n) | 252 | 1,221 | 148 | 442 | 462 | 752 | 511 | 176 | 529 |
| Age, years, median (range) | |||||||||
| Combination | 58 (28–82) | 53 (23–78) | 60 (32–82) | 52 (27–79) | 51 (29–78) | 53 (25–76) | 52 (26–79) | Not reported | 53 (26–83) |
| Single agent | 57 (35–80) | 53 (24–81) | 60 (34–82) | 54 (31–77) | 52 (30–77) | 52 (25–79) | 51 (25–75) | Not reported | 53 (27–75) |
| Regimens | GEM + NVB/NVB | IXA + CAP/CAP | NVB + GEM/CAP | Sunitinib + GEM/CAP | Bevacizumab + CAP/CAP | Ixabepilone + CAP/CAP | DOC + CAP/CAP | 5-FU + vinorelbine/DOC | GEM + paclitaxcel/paclitaxcel |
| Metastatic or recurrent (%) | Metastatic (100) | Metastatic (100) | Metastatic (100) | Metastatic (94), recurrent (6) | Metastatic (100) | Metastatic (100) | Metastatic (97), recurrent (3) | Metastatic (100) | Metastatic (97), recurrent (3) |
| Jadad score | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Line of therapy | First to third line | Any line | ≥2nd line | Not reported | Any line | Any line | First to third line | Not reported | Not reported |
| HER-2 positive (%) | |||||||||
| Combination | 15 | 14 | 14.9 | 13 | 26.3 | 16 | Not reported | Not reported | Not reported |
| Single agent | 15 | 16 | 12.2 | 11 | 20.4 | 14 | Not reported | Not reported | Not reported |
Abbreviations: GEM, gemcitabine; NVB, vinorelbine; IXA, ixabepilone; CAP, capecitabine; DOC, docetaxel; 5-FU, 5-fluorouracil.